Press release


26/01/2017
SOM Biotech closes a €2M financing round
SOM Biotech
SOM Biotech –a clinical-stage pharmaceutical company specialized in drug repositioning to treat rare diseases of the nervous system - has just closed a €2M financing round. The company will allocate this capital to boost its activities of internalization, co-development and licensing, as well as to finance a Ph2 of a drug for Huntington's, the 2nd asset of the company that reaches clinical stages.
 
 
Documentación:
 
 
 
Permalink  
 
Developed by Web4Bio